Is AOD-9604 Legal in Minnesota? How to Access It Legally

What Is AOD-9604 and Why Does Its Legal Status Matter?

AOD-9604 is a 16-amino-acid synthetic peptide corresponding to the C-terminal fragment of human growth hormone, specifically residues 176 through 191, with an added tyrosine at the N-terminus. Researchers originally developed it at Monash University in Australia to capture the fat-mobilizing activity of hGH without the insulin-desensitizing effects of the full 191-amino-acid molecule. Because peptides like this one sit at the intersection of drug law, compounding pharmacy regulation, and sports-supplement commerce, their legal classification matters enormously to any patient or clinician considering use.

Human growth hormone itself is a Schedule III controlled substance under the Controlled Substances Act when prescribed for non-approved purposes [1]. AOD-9604 is not classified as a controlled substance, but that does not make it freely available. The distinction between "not scheduled" and "legally accessible as a medicine" is wide, and Minnesota residents need to understand both layers.

The Monash University and Metabolic Pharmaceuticals Research Background

Metabolic Pharmaceuticals Pty Ltd conducted Phase I and Phase II clinical trials of AOD-9604 primarily in Australia between 1998 and 2007. A Phase IIb randomized controlled trial (N=300) evaluated oral AOD-9604 at doses of 1 mg/kg/day versus placebo over 12 weeks and reported approximately 2.0 kg greater weight reduction in the active arm [2]. The compound also received GRAS (Generally Recognized As Safe) status from the FDA for use as a food ingredient in 2014, a designation that applies specifically to its use in food, not as a therapeutic drug [3].

GRAS status is frequently misread as proof of therapeutic legality. It is not. A substance can be GRAS for food and simultaneously unapproved as a drug.

Why No Large Phase III Trial Exists

Metabolic Pharmaceuticals halted development before a Phase III trial. The company cited the commercial challenge of protecting a peptide patent long enough to recoup Phase III costs, a common barrier for peptide therapeutics [4]. Without Phase III data, the FDA has never reviewed AOD-9604 for drug approval through the New Drug Application (NDA) pathway, which is codified under 21 U.S.C. § 355 [5].

Federal FDA Status: The Controlling Legal Framework

Federal law governs drug approval and compounding in the United States, and it controls AOD-9604 access more than any Minnesota state statute does. The Federal Food, Drug, and Cosmetic Act (FD&C Act) requires that any substance marketed as a drug be proven safe and effective through the NDA or Biologics License Application (BLA) process [5]. AOD-9604 has cleared neither.

The 503A Compounding Restriction

Section 503A of the FD&C Act, added by the Drug Quality and Security Act of 2013, allows licensed pharmacists to compound drugs for individual patients based on a valid prescription, provided the active pharmaceutical ingredient (API) is on the FDA's approved bulk substances list or meets certain other criteria [6]. The FDA has published a list of bulk drug substances that may NOT be used in 503A compounding because they present safety concerns or lack sufficient evidence of clinical utility.

AOD-9604 has been nominated for inclusion on the 503A "Category 1" positive list (substances that may be compounded) but, as of the most recent FDA review cycles, has not received final positive listing. The FDA's Pharmacy Compounding Advisory Committee (PCAC) evaluated it and raised concerns about adequacy of clinical evidence [7]. Until a final rule places AOD-9604 on the affirmative 503A list, licensed 503A compounding pharmacies cannot legally compound it for patient use in Minnesota or any other state.

The 503B Outsourcing Facility Gap

Section 503B outsourcing facilities can produce larger batches without individual prescriptions, but only from substances on a separate FDA-approved bulk list [6]. AOD-9604 does not appear on that 503B list either. Patients should not expect to obtain AOD-9604 through a 503B outsourcing facility under current federal rules.

FDA Enforcement Discretion: A Real but Unstable Gray Zone

The FDA does not always immediately pursue enforcement against every 503A pharmacy that compounds an unapproved peptide. Some clinicians and compounders have operated in this discretionary space. Relying on enforcement discretion, however, means operating under a framework that can change without notice, as the FDA's 2023-2024 actions on semaglutide compounding demonstrated when it moved to end compounding once shortage designations changed [8]. Patients who begin treatment under enforcement discretion have no guarantee of continued supply.

Minnesota State Law: What It Does and Does Not Add

Minnesota does not have a state statute that specifically names AOD-9604, either to prohibit or to permit it. The Minnesota Board of Pharmacy regulates pharmacies and pharmacists operating within the state under Minnesota Statutes Chapter 151 [9]. That chapter incorporates federal compounding standards by reference for most practical purposes.

Minnesota's Medical Practice Act

The Minnesota Medical Practice Act (Minnesota Statutes Chapter 147) governs physicians and allows them to prescribe any legally available substance within the bounds of their professional judgment and standard of care [10]. A Minnesota-licensed physician can write a prescription for AOD-9604, and that act of prescribing is not itself illegal. The downstream problem is that a licensed pharmacy cannot legally fill that prescription under current federal 503A rules.

No State-Level Controlled Substance Analog Act Issues

Minnesota's Controlled Substances Act (Minnesota Statutes Chapter 152) schedules specific substances and analogs of scheduled drugs [11]. AOD-9604 is not scheduled federally and is not a structural analog of any federally scheduled drug under the definitions used in Chapter 152. Minnesota adds no separate scheduling for this peptide.

Minnesota Board of Pharmacy Stance

The Minnesota Board of Pharmacy has not issued a specific advisory opinion on AOD-9604 as of the date of this article's review. Clinicians and patients seeking the most current state-level guidance should contact the Board directly at mn.gov/boards/pharmacy. That step is not optional for any pharmacy considering compounding this peptide.

How Patients in Minnesota Can Attempt Legal Access

Given the constraints above, there are three realistic access paths, each with specific requirements and limitations.

Path 1: Clinical Trial Enrollment

The cleanest legal path is enrollment in a registered clinical trial. ClinicalTrials.gov lists studies involving AOD-9604 and related growth hormone fragment research [12]. Trial enrollment provides access under an Investigational New Drug (IND) exemption, which is the legally unambiguous route. Trials may be geographically limited and have strict inclusion criteria, typically body mass index (BMI) between 27 and 40 kg/m2 and absence of diabetes or major cardiovascular disease.

Path 2: Physician Evaluation and Compounding Pharmacy (Conditional)

A Minnesota-licensed physician can evaluate a patient, determine that AOD-9604 is appropriate for that patient's condition, and write a prescription. The prescription can only be filled if a 503A pharmacy is willing to compound it and if the FDA's enforcement posture at that moment permits it. Patients choosing this path should ask any prospective compounding pharmacy for written documentation of its legal rationale for compounding AOD-9604, including any relevant FDA guidance letters or advisory opinions it has received.

The HealthRX medical team uses the following four-question framework before any peptide is included in a Minnesota patient's treatment plan:

1. Is the peptide on the FDA 503A affirmative list? If yes, proceed. If no, move to question 2.
2. Is the FDA's current enforcement posture permissive for this substance? Document the answer with a dated review of FDA guidance.
3. Has the compounding pharmacy received a warning letter for this substance? Check FDA's public warning letter database at fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters.
4. Does the patient have a documented clinical indication (e.g., metabolic syndrome, BMI <40) and has a licensed physician evaluated the risk-benefit ratio in writing?

Only when all four questions yield acceptable answers does HealthRX's clinical team proceed.

Path 3: Research Use Under IRB Oversight

Licensed researchers at Minnesota institutions (University of Minnesota, Mayo Clinic, etc.) may obtain AOD-9604 as a research chemical through licensed API suppliers for use in IRB-approved protocols. This path is not available to general patients. It follows the FDA's IND framework under 21 C.F.R. Part 312 [13].

What the Clinical Evidence Actually Shows

Understanding why patients want AOD-9604 requires looking at the trial data honestly. The compound does have genuine pharmacological effects in human and animal studies, but the evidence base is thinner than many online sources suggest.

Weight Loss and Lipolysis Data

The Phase IIb trial by Metabolic Pharmaceuticals (N=300) showed approximately 2.0 kg greater weight loss versus placebo at 12 weeks with oral dosing at 1 mg/kg/day [2]. That effect size is modest. For comparison, the STEP-1 trial (N=1,961) of subcutaneous semaglutide 2.4 mg weekly showed 14.9% mean body weight reduction at 68 weeks versus 2.4% with placebo [14]. AOD-9604 does not approach semaglutide's magnitude of effect, though it operates through a different mechanism (direct lipolysis stimulation via beta-3 adrenergic receptors rather than GLP-1 receptor agonism).

Cartilage and Osteoarthritis Research

Separate from weight loss, researchers have studied AOD-9604 for cartilage repair and osteoarthritis. A study published in Growth Factors examined the peptide's ability to stimulate chondrogenesis in vitro and in animal models [15]. Clinical translation remains unproven. No completed Phase III osteoarthritis trial exists in the published literature indexed on PubMed [16].

IGF-1 and Insulin Sensitivity

One concern with full hGH therapy is insulin resistance mediated through IGF-1 elevation. AOD-9604 does not significantly raise IGF-1 at therapeutic doses tested in Phase II trials, which is a meaningful safety advantage over hGH [2]. The FDA's review of the GRAS petition noted this finding but did not interpret it as sufficient evidence for therapeutic approval [3].

Safety Profile From Trials

Adverse events reported in Phase II trials were generally mild: injection site reactions, headache, and transient flushing. No serious adverse events attributable to the compound were reported at doses up to 1 mg/kg/day orally [2]. Subcutaneous injection formulations, which are more common in current compounding contexts, were not studied in these Phase II trials, so injection-specific safety data are extrapolated from related peptide literature rather than direct AOD-9604 trial evidence.

The absence of serious adverse events in a Phase II trial of 300 patients over 12 weeks does not establish long-term safety. The FDA requires substantially more data for drug approval for good reason [5].

Risks of Obtaining AOD-9604 From Unregulated Sources

Patients who cannot access AOD-9604 through legal compounding channels sometimes turn to online vendors selling it as a "research chemical." This practice carries specific, documentable risks that go beyond legal jeopardy.

Product Purity and Verification

A 2020 study in JAMA Internal Medicine analyzing peptide products sold online found that a significant proportion contained incorrect concentrations, contaminants, or substituted substances [17]. The FDA does not inspect research chemical vendors' manufacturing processes. Patients injecting unverified peptide products bypass every quality-control safeguard that the FD&C Act and Good Manufacturing Practice (GMP) regulations provide [18].

Legal Risk to the Patient

Purchasing AOD-9604 labeled "not for human use" and then using it for human use does not insulate a buyer from FDA enforcement, though individual prosecutions are rare. More practically, a patient who experiences an adverse event from an unverified product has no recourse under standard product liability frameworks because the vendor explicitly disclaimed human use.

Legal Risk to the Prescriber

A Minnesota-licensed physician who recommends that a patient purchase from an unregulated online vendor faces potential disciplinary action from the Minnesota Board of Medical Practice under the standard-of-care provisions of Chapter 147 [10]. Recommending unverified products is categorically different from prescribing through a licensed pharmacy.

How Telehealth Providers Like HealthRX Approach AOD-9604 in Minnesota

Telehealth providers operating in Minnesota must hold Minnesota physician or advanced practice provider licenses and comply with both the Minnesota Telehealth Act and federal prescribing laws. HealthRX physicians follow these specific steps for any patient inquiring about AOD-9604:

Step 1: Full Clinical Evaluation

A board-certified physician conducts a synchronous video visit covering medical history, current medications, metabolic labs (fasting glucose, HbA1c, lipid panel, IGF-1, and comprehensive metabolic panel), and weight history. This is not optional. The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy specifies that provider evaluation must precede any pharmacological intervention [19].

Step 2: FDA Status Review at Time of Consultation

Because the FDA's compounding policy for specific peptides can change, HealthRX clinicians verify the current 503A status of AOD-9604 at the time of each consultation rather than relying on standing protocols. The FDA's compounding guidance documents are updated and available at fda.gov/drugs/human-drug-compounding [7].

Step 3: Documented Informed Consent

Patients receive a written informed consent document specifying: (a) the FDA approval status of AOD-9604, (b) the current compounding regulatory status, (c) the evidence base and its limitations, and (d) alternative FDA-approved treatments available for the patient's indication. The American Society of Anesthesiologists' framework for off-label consent informs this process, and similar standards apply to off-label prescribing in general [20].

Step 4: Referral to Licensed Pharmacy Only

HealthRX refers patients only to 503A-compliant compounding pharmacies that have confirmed, in writing, their legal basis for compounding AOD-9604. If no such pharmacy is currently available, HealthRX does not support AOD-9604 access and discusses alternative therapies instead.

Alternatives to AOD-9604 With Stronger Regulatory Standing in Minnesota

Patients seeking metabolic support or weight management in Minnesota have access to several FDA-approved options that carry no legal ambiguity.

Semaglutide 2.4 mg (Wegovy) is FDA-approved for chronic weight management in adults with BMI >30 or BMI >27 with at least one weight-related comorbidity. STEP-1 demonstrated 14.9% mean weight loss at 68 weeks [14]. Tirzepatide 2.5-15 mg (Zepbound) received FDA approval in November 2023 for the same indication and demonstrated up to 20.9% mean weight loss in the SURMOUNT-1 trial (N=2,539) at 72 weeks [21].

Sermorelin, a growth hormone-releasing hormone analog, is FDA-approved for growth hormone deficiency and is on the 503A positive compounding list, making it a legally cleaner alternative for patients seeking peptide-based therapy with some metabolic benefit [22].

Key Takeaways for Minnesota Patients and Clinicians

AOD-9604 is not a controlled substance in Minnesota or federally. A physician can legally write a prescription for it. The blocking issue is the federal compounding framework: without FDA placement on the 503A affirmative list, licensed pharmacies face significant legal risk in filling that prescription.

The GRAS food designation does not equal drug approval. Phase IIb data show a real but modest weight-loss effect. No Phase III trial exists. Long-term safety data from controlled trials are absent.

Patients who want to pursue AOD-9604 in Minnesota should start with a licensed physician evaluation, ask specifically about the current FDA compounding status, and never purchase from unregulated online vendors regardless of how the product is labeled.

The FDA's current publicly available guidance on AOD-9604 compounding can be found at fda.gov/drugs/human-drug-compounding, and Minnesota patients with pharmacy-specific questions should contact the Minnesota Board of Pharmacy directly. A physician consultation is the required first step for any patient pursuing peptide therapy in Minnesota; call HealthRX to schedule that evaluation before ordering anything.